Expert Consensus on Diagnosis and Molecular Testing Strategies for Non-Small-Cell Lung Cancer in India

Abstract

This review aims to establish expert consensus on biomarker testing for non-small-cell lung cancer (NSCLC) in India, evaluating diagnostic practices, adherence to international guidelines, and test utility and comparing clinically validated assays with laboratory-developed tests. In round 1, experts voted on 41 statements covering various aspects of NSCLC diagnostics. Responses were graded using a 5-point Likert scale, categorizing agreement levels as high, moderate, or low based on expert consensus percentages. After thorough deliberations during round 2, consensus was reached on 32 statements underscoring the necessity for early diagnosis of NSCLC. Key issues include misdiagnosis with tuberculosis and low or delayed specialist referral rates. Although formal programs are limited by awareness, resources, and data gaps; low-dose computed tomography (LDCT) screening in community settings is advocated. Consensus was reached among experts that most lung cancers are diagnosed at advanced stages in India. The delay in diagnosis was mainly due to misdiagnosis with tuberculosis and delayed referrals to specialists for evaluation. The consensus acknowledged the need to enhance lung cancer awareness and utilization of LDCT in high-risk individuals as a screening methodology in the community.

Biomarker testing for both early-stage and advanced-stage NSCLC is recommended, with reflex testing at diagnosis, longitudinal testing at disease progression, and liquid biopsies when tissue is unavailable/inadequate. Biomarker testing for common driver mutations associated with available targeted therapies can be performed in resource-limited settings using sequential testing or hotspot panels. PD-L1 testing for all advanced-stage cases is recommended, especially when molecular driver mutations/fusions are negative. Despite longer turnaround times, next-generation sequencing (NGS) would be preferred for its comprehensive gene assessment. Multigene assays are recommended for advanced stages, and upfront broad-panel tests are ideal. Testing for EGFR, ALK, proto-oncogene ROS1, and PD-L1 is essential for NSCLC. We urge standardized histopathological and molecular practices and acknowledge challenges in NGS availability and the complexities of interpreting results. This consensus underscores the importance of streamlined approaches to enhance NSCLC diagnostics in resource-constrained settings in India.

Keywords

non-small-cell lung cancer - next-generation sequencing - biomarkers - companion diagnostic - reflex testing - targeted therapies - low-dose computed tomography

Author's Contributions

The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and each author believes that the manuscript represents honest work. B.B.: concepts, design, literature search, manuscript preparation, manuscript editing, manuscript review; T.P.: concepts, design, literature search, manuscript preparation, manuscript editing, manuscript review; N.R.: literature search, manuscript editing, manuscript review; V.M.N.: literature search, manuscript editing, manuscript review; B.K.: literature search, manuscript editing, manuscript review; A.S.: literature search, manuscript editing, manuscript review; S.P.: literature search, manuscript editing, manuscript review; J.D.: concepts, design, literature search, manuscript preparation, manuscript editing, manuscript review; S.L.: concepts, design, literature search, manuscript preparation, manuscript editing, manuscript review.

Patient's Consent

No patient data was used in this article. Hence patient consent is not applicable for this manuscript.

Publication History

Article published online:
19 June 2025

• References

• 1 Ferlay J, Ervik M, Lam F. et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Accessed May 27, 2024 at: https://gco.iarc.who.int/today
• 2 Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol 2024; 93: 102693
• 3 Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: result from National Cancer Registry Programme, India. Indian J Med Res 2022; 156 (4 & 5): 598-607
• 4 Alduais Y, Zhang H, Fan F, Chen J, Chen B. Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment. Medicine (Baltimore) 2023; 102 (08) e32899
• 5 Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 2019; 94 (08) 1623-1640
• 6 Nath A, Sathishkumar K, Das P, Sudarshan KL, Mathur P. A clinicoepidemiological profile of lung cancers in India - results from the National Cancer Registry Programme. Indian J Med Res 2022; 155 (02) 264-272
• 7 Ninatti G, Kirienko M, Neri E, Sollini M, Chiti A. Imaging-based prediction of molecular therapy targets in NSCLC by radiogenomics and AI approaches: a systematic review. Diagnostics (Basel) 2020; 10 (06) 359
• 8 Singh N, Agrawal S, Jiwnani S. et al. Lung cancer in India. J Thorac Oncol 2021; 16 (08) 1250-1266
• 9 Mohan A, Garg A, Gupta A. et al. Clinical profile of lung cancer in North India: a 10-year analysis of 1862 patients from a tertiary care center. Lung India 2020; 37 (03) 190-197
• 10 National Cancer Institute. SEER cancer stat facts: lung and bronchus cancer. Accessed May 29, 2024 at: https://seer.cancer.gov/statfacts/html/lungb.html
• 11 Mitsudomi T, Tan D, Yang JC. et al. Expert consensus recommendations on biomarker testing in metastatic and nonmetastatic NSCLC in Asia. J Thorac Oncol 2023; 18 (04) 436-446
• 12 Central Drugs Standard Control Organization. New drugs approved by CDSCO. Accessed Feb 6, 2024 at: https://cdscoonline.gov.in/CDSCO/Drugs
• 13 U.S. Food and Drug Administration. . Drug approvals and databases. Accessed Feb 6, 2024 at: https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases
• 14 Mazzone PJ, Sears CR, Arenberg DA. et al; ATS Assembly on Thoracic Oncology. Evaluating molecular biomarkers for the early detection of lung cancer: when is a biomarker ready for clinical use? An official American Thoracic Society Policy Statement. Am J Respir Crit Care Med 2017; 196 (07) e15-e29
• 15 Conde E, Rojo F, Gómez J. et al. Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing. J Clin Pathol 2022; 75 (03) 145-153
• 16 Ettinger DS, Wood DE, Aisner DL. et al. Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20 (05) 497-530
• 17 Lindeman NI, Cagle PT, Aisner DL. et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol 2018; 13 (03) 323-358
• 18 Hendriks LE, Kerr KM, Menis J. et al; ESMO Guidelines Committee. Electronic address: [e-mail]. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34 (04) 339-357
• 19 Prabhash K, Advani SH, Batra U. et al. Biomarkers in non-small cell lung cancers: Indian Consensus Guidelines for Molecular Testing. Adv Ther 2019; 36 (04) 766-785
• 20 Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: How to decide its appropriateness. World J Methodol 2021; 11 (04) 116-129
• 21 Centre for Evidence-Based Medicine. Oxford Centre for Evidence-Based Medicine: levels of evidence (March 2009). Accessed February 6, 2024 at: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009
• 22 Vashistha V, Choudhari C, Garg A. et al. The time required to diagnose and treat lung cancer in Delhi, India: an updated experience of a public referral center. Appl Cancer Res 2019; 39: 11
• 23 Osarogiagbon RU, Liao W, Faris NR. et al. Lung cancer diagnosed through screening, lung nodule, and neither program: a prospective observational study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta Cohort. J Clin Oncol 2022; 40 (19) 2094-2105
• 24 Shankar A, Saini D, Dubey A. et al. Feasibility of lung cancer screening in developing countries: challenges, opportunities and way forward. Transl Lung Cancer Res 2019; 8 (Suppl. 01) S106-S121
• 25 Crane M, Scott N, O'Hara BJ. et al. Knowledge of the signs and symptoms and risk factors of lung cancer in Australia: mixed methods study. BMC Public Health 2016; 16: 508
• 26 Fu F, Zhou Y, Zhang Y, Chen H. Lung cancer screening strategy for non-high-risk individuals: a narrative review. Transl Lung Cancer Res 2021; 10 (01) 452-461
• 27 Aberle DR, Adams AM, Berg CD. et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365 (05) 395-409
• 28 Teles GBDS, Macedo ACS, Chate RC, Valente VAT, Funari MBG, Szarf G. LDCT lung cancer screening in populations at different risk for lung cancer. BMJ Open Respir Res 2020; 7 (01) e000455
• 29 Poon C, Wilsdon T, Sarwar I, Roediger A, Yuan M. Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption. Front Public Health 2023; 11: 1264342
• 30 Biswas B, Talwar D, Meshram P. et al. Navigating patient journey in early diagnosis of lung cancer in India. Lung India 2023; 40 (01) 48-58
• 31 Vora A, Balamugesh T, Behera D. et al. Screening for lung cancer in India: expert opinion statement. J Assoc Physicians India 2024; 72 (05) e1-e16
• 32 Parang S, Bhavin J. LDCT screening in smokers in India-a pilot, proof-of-concept study. Indian J Radiol Imaging 2021; 31 (02) 318-322
• 33 Gosney JR, Paz-Ares L, Jänne P. et al. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation. ESMO Open 2023; 8 (04) 101587
• 34 Cheema PK, Menjak IB, Winterton-Perks Z. et al. Impact of reflex EGFR/ALK testing on time to treatment of patients with advanced nonsquamous non-small-cell lung cancer. J Oncol Pract 2017; 13 (02) e130-e138
• 35 Nambirajan A, Husain N, Shukla S, Kumar S, Jain D. Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma. Indian J Med Res 2019; 150 (04) 376-384
• 36 Pennell NA, Arcila ME, Gandara DR, West H. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book 2019; 39: 531-542
• 37 Gregg JP, Li T, Yoneda KY. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. Transl Lung Cancer Res 2019; 8 (03) 286-301
• 38 Nakra T, Mehta A, Bal A. et al. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: multi-institutional data discussion at national conference of “Lung Cancer Management in Indian context”. Curr Probl Cancer 2020; 44 (03) 100561
• 39 Wu YL, Sequist LV, Hu CP. et al. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer 2017; 116 (02) 175-185
• 40 Raez LE, Brice K, Dumais K. et al. Liquid biopsy versus tissue biopsy to determine front line therapy in metastatic non-small cell lung cancer (NSCLC). Clin Lung Cancer 2023; 24 (02) 120-129
• 41 Papadopoulou E, Tsoulos N, Tsantikidi K. et al. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients. PLoS One 2019; 14 (12) e0226853
• 42 Uruga H, Mino-Kenudson M. ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients. Pharm Genomics Pers Med 2018; 11: 147-155
• 43 Nambirajan A, Sood R, Khatoon W, Malik PS, Mohan A, Jain D. Concordance of immunohistochemistry and fluorescence in situ hybridization in the detection of anaplastic lymphoma kinase (ALK) and Ros proto-oncogene 1 (ROS1) gene rearrangements in non-small cell lung carcinoma: a 4.5-year experience highlighting challenges and pitfalls. Arch Pathol Lab Med 2024; 148 (08) 928-937
• 44 Godre N, Gupta V, Alam M. Concordance analysis of IHC and FISH in the detection of ROS1 gene rearrangement in NSCLC: results of a meta-analysis. ESMO 2017; 28: X140-X141
• 45 Koyama K, Miura S, Watanabe S. et al. Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC. Sci Rep 2022; 12 (01) 6367
• 46 Prince EA, Sanzari JK, Pandya D, Huron D, Edwards R. Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review. JCO Precis Oncol 2021; 5: 953-973
• 47 Maule JG, Clinton LK, Graf RP. et al. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. J Immunother Cancer 2022; 10 (10) e005573
• 48 Franzi S, Seresini G, Borella P. et al. Liquid biopsy in non-small cell lung cancer: a meta-analysis of state-of-the-art and future perspectives. Front Genet 2023; 14: 1254839
• 49 de Jager VD, Timens W, Bayle A. et al. Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer. Lancet Reg Health Eur 2024; 38: 100839
• 50 Shukla S, Pandey RK, Kant S. et al. Detection of anaplastic lymphoma kinase gene re-arrangement in non-small cell lung carcinoma in the Indian population: comparison of techniques and immunohistochemistry clones. Turk Patoloji Derg 2019; 35 (01) 36-45
• 51 Nesline MK, Subbiah V, Previs RA. et al. The impact of prior single-gene testing on comprehensive genomic profiling results for patients with non-small cell lung cancer. Oncol Ther 2024; 12 (02) 329-343
• 52 Dall'Olio FG, Conci N, Rossi G. et al. Comparison of sequential testing and next generation sequencing in advanced lung adenocarcinoma patients - a single centre experience. Lung Cancer 2020; 149: 5-9
• 53 Rolfo C, Mack PC, Scagliotti GV. et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol 2018; 13 (09) 1248-1268
• 54 Malapelle U, Tiseo M, Vivancos A, Kapp J, Serrano MJ, Tiemann M. Liquid biopsy for biomarker testing in non-small cell lung cancer: a European perspective. J Mol Pathol 2021; 2: 255-273
• 55 Li W, Liu JB, Hou LK. et al. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer 2022; 21 (01) 25
• 56 Smeltzer MP, Wynes MW, Lantuejoul S. et al. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. J Thorac Oncol 2020; 15 (09) 1434-1448
• 57 Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 2019; 20 (02) 71-88
• 58 Bonanno L, Dal Maso A, Pavan A. et al. Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. Br J Cancer 2022; 127 (03) 383-393
• 59 Li MSC, Mok KKS, Mok TSK. Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review. Ann Transl Med 2023; 11 (10) 358
• 60 Murthy SS, Rajappa SJ, Gundimeda SD. et al. Anaplastic lymphoma kinase status in lung cancers: an immunohistochemistry and fluorescence in situ hybridization study from a tertiary cancer center in India. Indian J Cancer 2017; 54 (01) 231-235
• 61 Doval D, Prabhash K, Patil S. et al. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. OncoTargets Ther 2015; 8: 117-123
• 62 Saw SPL, Zhong WZ, Fu R. et al. Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer. Lung Cancer 2025; 200: 108076
• 63 Aguiar Jr PN, De Mello RA, Hall P, Tadokoro H, Lima Lopes G. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy 2017; 9 (06) 499-506
• 64 Vallonthaiel AG, Malik PS, Singh V. et al. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: a report from India. Ann Diagn Pathol 2017; 31: 56-61
• 65 Batra U, Nathany S. Biomarker testing in lung cancer: from bench to bedside. Oncol Rev 2025; 18: 1445826
• 66 Owen D, Ben-Shachar R, Feliciano J. et al. Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer. JAMA Netw Open 2024; 7 (11) e2442970
• 67 Desmeules P, Boudreau DK, Bastien N. et al. Performance of an RNA-based next-generation sequencing assay for combined detection of clinically actionable fusions and hotspot mutations in NSCLC. JTO Clin Res Rep 2022; 3 (02) 100276
• 68 Zheng Y, Vioix H, Liu FX, Singh B, Sharma S, Sharda D. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review. Future Oncol 2022; 18 (04) 505-518
• 69 Mathew A, Joseph S, Boby J. et al. Clinical benefit of comprehensive genomic profiling for advanced cancers in India. JCO Glob Oncol 2022; 8: e2100421
• 70 Schmid S, Jochum W, Padberg B. et al. How to read a next-generation sequencing report-what oncologists need to know. ESMO Open 2022; 7 (05) 100570
• 71 Amrith B, Sharma M, Jain P. et al. NGS in advanced NSCLC in a developing country: ready for prime time?. ESMO 2019; 30 (09) ix127
• 72 Mehta A, Vasudevan S, Sharma S. et al. Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscape. Appl Cancer Res 2020; 40: 1-12
• 73 Batra U, Nathany S, Sharma M. et al. 395P Molecular landscape of Indian NSCLC: is NGS the answer?. Ann Oncol 2022; 33: S1596
• 74 Gupta P, Saha K, Vinarkar S. et al. Next generation sequencing in lung cancer: an initial experience from India. Curr Probl Cancer 2020; 44 (03) 100562-100573
• 75 Perdrizet K, Stockley TL, Law JH. et al. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. Cancer Treat Res Commun 2022; 31: 100534-100541